Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches

2013 Alzheimer's disease facts and figures

(2013)   Alzheimers & Dementia

Relevance of Magnetic Resonance Imaging for Early Detection and Diagnosis of Alzheimer Disease

(2013) Stefan J. Teipel et al.   MEDICAL CLINICS OF NORTH AMERICA

Plasma Amyloid-β as a Predictor of Dementia and Cognitive Decline

(2012) Alain Koyama et al.   ARCHIVES OF NEUROLOGY

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

(2012) Vladimir Coric et al.   ARCHIVES OF NEUROLOGY

Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis

(2012) Petra Dunkel et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Identification of BACE2 as an avid ß-amyloid-degrading protease

(2012) Samer O Abdul-Hay et al.   Molecular Neurodegeneration

Alzheimer’s drugs take a new tack

(2012) Ewen Callaway   NATURE

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

(2012) Thorlakur Jonsson et al.   NATURE

Sting of Alzheimer's failures offset by upcoming prevention trials

(2012) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Clinical and Research Diagnostic Criteria for Alzheimer's Disease

(2012) Marie Sarazin et al.   NEUROIMAGING CLINICS OF NORTH AMERICA

CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings

(2012) T. T. Seppala et al.   NEUROLOGY

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Combination Therapy for Alzheimerʼs Disease

(2011) Laxeshkumar Patel et al.   DRUGS & AGING

Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease

(2011) Sherry L. La Porte et al.   JOURNAL OF MOLECULAR BIOLOGY

Robust Central Reduction of Amyloid-  in Humans with an Orally Available, Non-Peptidic  -Secretase Inhibitor

(2011) P. C. May et al.   JOURNAL OF NEUROSCIENCE

Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease

(2009) David B Henley et al.   EXPERT OPINION ON PHARMACOTHERAPY

Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease

(2009) N. Nelissen et al.   JOURNAL OF NUCLEAR MEDICINE

Gamma-Secretase Represents a Therapeutic Target for the Treatment of Invasive Glioma Mediated by the p75 Neurotrophin Receptor

(2008) LiMei Wang et al.   PLOS BIOLOGY